NCT00004125已完成3 期
A Phase III Study of Doxorubicin-Cyclophosphamide Therapy Followed by Paclitaxel or Docetaxel Given Weekly or Every 3 Weeks in Patients With Axillary Node-Positive Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 试验地点
- 48
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating women who have stage II or stage IIIA breast cancer that has spread to the lymph nodes.
详细描述
OBJECTIVES:
- Compare the disease-free survival and overall survival in patients with node-positive or high-risk node-negative operable stage II or IIIA breast cancer treated with docetaxel or paclitaxel after doxorubicin and cyclophosphamide.
- Determine whether the weekly administration of paclitaxel or docetaxel for 12 weeks improves disease-free survival and overall survival when compared with the conventional schedule of every 3 weeks for 4 courses after doxorubicin and cyclophosphamide in this patient population.
- Compare the toxic effects of docetaxel and paclitaxel when administered weekly for 12 weeks versus every 3 weeks for 4 courses in these patients.
- Compare the toxicity of paclitaxel administered every 3 weeks for 4 courses or weekly for 12 weeks to that of docetaxel administered on the same schedules in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to estrogen receptor status (positive vs negative vs unknown), nodal status (0 positive nodes vs 1-3 positive nodes vs 4-9 positive nodes vs at least 10 positive nodes), tumor size (no more than 5 cm vs more than 5 cm vs unknown), and type of prior surgery (mastectomy vs breast conservation surgery). Patients are randomized to one of four treatment arms.
- Arm I: Patients receive doxorubicin IV and cyclophosphamide IV every 3 weeks for 4 courses (weeks 1-12). Beginning at week 13, patients receive paclitaxel IV over 3 hours every 3 weeks for 4 courses.
- Arm II: Patients receive doxorubicin and cyclophosphamide as in arm I. Beginning at week 13, patients receive paclitaxel IV over 1 hour weekly for 12 weeks.
- Arm III: Patients receive doxorubicin and cyclophosphamide as in arm I. Beginning at week 13, patients receive docetaxel IV over 1 hour every 3 weeks for 4 courses.
- Arm IV: Patients receive doxorubicin and cyclophosphamide as in arm I. Beginning at week 13, patients receive docetaxel IV over 1 hour weekly for 12 weeks.
Within 4 weeks after completion of chemotherapy, patients with estrogen and/or progesterone receptor positive tumors receive oral tamoxifen daily for 5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed operable stage IIA, IIB, or IIIA adenocarcinoma of the breast with histologically involved lymph nodes (T1, 2, or 3; N1 or 2; M0) OR high-risk node-negative disease (T2 or 3; N0)
- •Primary tumor at least 2.1 cm in diameter for node-negative disease
- •Bilateral breast disease allowed if at least 1 primary tumor meets the criteria above
- •Must have had at least 6 axillary lymph nodes removed at dissection and at least one node positive for metastasis OR
- •Sentinel node biopsy negative for metastasis (sentinel node biopsy positive allowed if enrolled on American College of Surgery Trial Z0011 and have beenrandomized to receive no axillary dissection)
- •Additional axillary nodes may be obtained provided they are also negative for metastasis
- •Complete tumor removal by either a modified radical mastectomy or local excision plus axillary lymph node dissection (i.e., breast conservation therapy) or sentinel node biopsy
- •Tumor-free margins at least 1 mm for both invasive and noninvasive carcinoma except for lobular carcinoma in situ (less than 1 mm allowed)
- •Concurrent enrollment on American College of Surgery Trial Z0010, Z0011, or NSABP B-32 allowed
- •Hormone receptor status:
- •Estrogen receptor status positive, negative, or unknown
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Menopausal status:
- •Not specified
- •Performance status:
- •Not specified
- •Life expectancy:
- •Not specified
- •Hematopoietic:
- •Neutrophil count at least 1,500/mm^3
- •Platelet count at least 100,000/mm^3
- •Bilirubin no greater than 1.5 mg/dL
- •SGOT no greater than 2 times upper limit of normal
- •Creatinine no greater than 1.5 mg/dL
- •Cardiovascular:
- •No history of myocardial infarction
- •No congestive heart failure
- •No significant ischemic or valvular heart disease
- •No other prior invasive malignancies within the past 5 years except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix
- •No hypersensitivity to paclitaxel or docetaxel or other similarly formulated drugs (with Cremophor or polysorbate)
- •Not pregnant or nursing
- •Fertile patients must use effective barrier contraception
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy:
- •Not specified
- •Chemotherapy:
- •No prior chemotherapy for breast cancer
- •Endocrine therapy:
- •Prior tamoxifen of no more than 4 weeks duration for breast cancer allowed
- •Prior tamoxifen or other selective estrogen receptor modulator (SERM) for chemoprevention (e.g., Breast Cancer Prevention Trial) or for other indications (e.g., osteoporosis) allowed
- •No concurrent tamoxifen or other SERMs
- •Radiotherapy:
- •No prior radiotherapy for this malignancy
- •At least 2 weeks since prior radiotherapy to the breast for ductal carcinoma in situ
- •See Disease Characteristics
- •Less than 84 days since prior surgical procedure to adequately treat primary tumor
排除标准
- 未提供
研究者
研究点 (48)
Loading locations...
相似试验
Unknown
3 期
Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung CancerLung CancerNCT00003696Commissie Voor Klinisch Toegepast Onderzoek250
已完成
2 期
Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone CancerKidney CancerSarcomaNCT00002466Memorial Sloan Kettering Cancer Center
Unknown
2 期
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone TherapyPainProstate CancerNCT00005960Amgen
已完成
3 期
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian CancerPeritoneal Cavity CancerOvarian CancerNCT00043082SWOG Cancer Research Network61
已完成
1 期
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast CancerBreast CancerNCT00002837M.D. Anderson Cancer Center21